How should proton‑pump inhibitors be prescribed and monitored in a patient with chronic kidney disease, and what are alternative acid‑suppression options?

Proton Pump Inhibitors in CKD: Prescribing and Monitoring

In patients with CKD, PPIs should be prescribed only when a clear indication exists, using the lowest effective dose (typically once-daily), with regular review for de-prescribing opportunities, while considering potassium-competitive acid blockers (P-CABs) as a potentially safer alternative for long-term acid suppression.

Core Prescribing Principles

Establish and Document Clear Indication

Every CKD patient on a PPI requires documented justification for ongoing use 1. The primary care provider should regularly review whether the indication remains valid. Without an ongoing indication, the PPI can only cause harm through pill burden, costs, and potential adverse effects 1.

Definitive long-term indications in CKD patients include:

• Barrett's esophagus
• Severe erosive esophagitis (LA grade C/D)
• History of esophageal ulcer or peptic stricture
• Gastroprotection in high-risk NSAID/aspirin users
• Secondary prevention of peptic ulcers 1

Patients who should NOT be de-prescribed:

• Complicated GERD with severe erosive disease
• Barrett's esophagus or eosinophilic esophagitis
• High risk for upper GI bleeding 1

Dose Optimization Strategy

Step down twice-daily dosing to once-daily in most CKD patients with chronic PPI indications 1. Double-dose PPIs lack FDA approval and RCT evidence, yet 15% of users receive higher-than-standard doses. Higher doses increase costs and show stronger associations with adverse events including community-acquired pneumonia, hip fracture, and C. difficile infection 1.

CKD-Specific Safety Concerns

Renal Risks

Long-term PPI use in CKD associates with:

• Acute interstitial nephritis (AIN)
• Hypomagnesemia
• Potential progression to end-stage kidney disease
• Increased all-cause mortality 2, 3, 4

Critical caveat: All studies demonstrating these associations are observational and cannot establish causality. Randomized controlled trials comparing PPIs with placebo have NOT shown higher rates of adverse events 1. However, the absence of RCT evidence of harm does not justify inappropriate use.

Monitoring Requirements

For CKD patients on PPIs, monitor:

• Serum magnesium levels (hypomagnesemia risk)
• Kidney function trends (creatinine, eGFR)
• Signs/symptoms of acute interstitial nephritis
• Ongoing indication validity 2, 3

Alternative: Potassium-Competitive Acid Blockers

Emerging evidence strongly favors P-CABs over PPIs for renal safety in CKD patients. Two recent 2026 studies demonstrate:

• 63% lower risk of composite renal replacement therapy initiation (HR 0.63,95% CI 0.45-0.88) with P-CABs versus PPIs 5
• 48% lower risk of creatinine doubling (adjusted HR 0.52,95% CI 0.37-0.74) 6
• 37% lower risk of eGFR decline ≥50% (adjusted HR 0.63,95% CI 0.46-0.87) 6

P-CABs should be considered as first-line acid suppression in CKD patients requiring long-term therapy, particularly those with moderate-to-severe CKD or at high risk for progression 5, 6.

De-Prescribing Algorithm

Step 1: Identify Candidates

All CKD patients without definitive chronic indication should be considered for de-prescribing 1. Most GERD patients have non-erosive disease and may not require indefinite therapy.

Step 2: De-Prescribing Method

Choose either:

• Abrupt discontinuation, OR
• Dose tapering

Both approaches are acceptable 1. The decision should be based solely on lack of indication, NOT on concern for adverse events. The presence of a PPI-associated adverse event is NOT an independent indication for withdrawal 1.

Step 3: Patient Counseling

Warn patients about rebound acid hypersecretion: transient upper GI symptoms may develop after discontinuing long-term PPI therapy 1. This is temporary and should not be misinterpreted as need for continued therapy.

Step 4: Risk Assessment

Before de-prescribing, assess upper GI bleeding risk using an evidence-based strategy. High-risk patients should NOT be de-prescribed 1.

Common Pitfalls to Avoid

1. Do not discontinue PPIs in complicated GERD (severe erosive esophagitis, Barrett's, strictures) 1
2. Do not let observational adverse event data drive inappropriate discontinuation when strong indications exist 1
3. Do not continue twice-daily dosing without attempting step-down to once-daily 1
4. Do not prescribe without documented indication - this is the most common error 1
5. Do not ignore over-the-counter PPI use - physicians may be unaware of patient self-medication 1

Integration with CKD Management

The KDIGO 2024 CKD guidelines 7 emphasize RAS inhibitors, SGLT2 inhibitors, and mineralocorticoid receptor antagonists as cornerstone therapies. PPIs should not interfere with these evidence-based CKD treatments. However, monitor for drug interactions and ensure PPI use doesn't contribute to polypharmacy that reduces adherence to critical CKD medications.

In hospitalized nephrology patients, 46% experience PPI-related drug problems, most commonly involving inappropriate drug selection and excessive treatment duration 8. Systematic pharmaceutical review substantially improves rational PPI use in this population.